Oskira-3: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To a Tumor Necrosis Factor-alpha Antagonist. Genovese, M., van der Heijde, D., Keystone, E., Spindler, A., Benhamou, C., Kavanaugh, A., Fudman, E., Lampl, K., O'Brien, C., Duffield, E., Poiley, J., Weinblatt, M. WILEY-BLACKWELL. 2013: S199–S200

View details for Web of Science ID 000325359201455